Glenmark Pharma Announcements
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 19, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Authorized Generic to Milnacipran...
19 Mar, 2026 | 10:49am • Source: NSE
Glenmark Pharmaceuticals Inc., USA launches Authorised Generic to Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg
19 Mar, 2026 | 08:37am • Source: BSE
Glenmark Therapeutics Inc., USA launches Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)
19 Mar, 2026 | 08:32am • Source: BSE
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 16, 2026, titled "Glenmark Pharmaceuticals Inc., USA to launchPotassium Phosphates Injection USP,...
16 Mar, 2026 | 10:14am • Source: NSE
Glenmark Pharmaceuticals Inc., USA to launch Potassium Phospohates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P /...
16 Mar, 2026 | 08:45am • Source: BSE
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 04, 2026, titled "Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone...
04 Mar, 2026 | 10:11am • Source: NSE
Glenmark Specialty SA Receives U.S. FDA approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, with 180-Day Competitive Generic Therapy Exclusivity
04 Mar, 2026 | 08:37am • Source: BSE
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 27, 2026, titled "Glenmark Pharmaceuticals Inc., USA to launch Sodium Phosphates Injection...
27 Feb, 2026 | 10:40am • Source: NSE
Glenmark Pharmaceuticals Inc., USA to launch Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM...
27 Feb, 2026 | 09:21am • Source: BSE
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - ESG Ratings
20 Feb, 2026 | 05:29pm • Source: BSE
Newspaper advertisement regarding Notice of Special Window for Transfer and Dematerialisation of physical shares
18 Feb, 2026 | 04:26pm • Source: BSE
The transcript of the Earnings Call held on Monday, February 02, 2026 has been uploaded on the Company''s website.
04 Feb, 2026 | 03:16pm • Source: BSE
Pursuant to the relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform the details of Analyst /...
02 Feb, 2026 | 04:39pm • Source: BSE
Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we...
02 Feb, 2026 | 01:38pm • Source: BSE
Disclosure under Regulation 30 of the SEBI (LODR) Regulation, 2015 - Regulatory Action/ Inspection
31 Jan, 2026 | 09:16pm • Source: BSE
Enclosed please find herewith the details of Earnings Call slated for Monday, February 02, 2026 at 8:30 a.m. - 9:30 a.m. (IST), for your information...
22 Jan, 2026 | 04:44pm • Source: BSE
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") - ESG Rating.
05 Jan, 2026 | 04:43pm • Source: BSE
Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 30 mg/ 30 mL (1 mg/mL) Multiple - Dose Vial
23 Dec, 2025 | 08:44am • Source: BSE
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 11, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch Leucovorin Calcium for...
11 Dec, 2025 | 11:15am • Source: NSE
Glenmark Pharmaceuticals Inc., USA to launch Leucovorin Calcium for Injection USP, 350 mg/ vial Single - Dose Vial
11 Dec, 2025 | 08:44am • Source: BSE